Cargando…
New Markers of Disease Progression in Myelofibrosis
SIMPLE SUMMARY: Disease progression and prognosis in PMF are usually associated with worsening of anemia, increase of circulating blasts, and, more recently, with the presence, in addition to the “classical” driver mutations, of JAK2, MPL, and CALR genes, as well as of cytogenetic and molecular abno...
Autores principales: | Campanelli, Rita, Massa, Margherita, Rosti, Vittorio, Barosi, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582535/ https://www.ncbi.nlm.nih.gov/pubmed/34771488 http://dx.doi.org/10.3390/cancers13215324 |
Ejemplares similares
-
Constitutive STAT5 phosphorylation in CD34(+) cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity
por: Abbà, Carlotta, et al.
Publicado: (2019) -
VEGFA rs3025039 is associated with phenotype severity of myelofibrosis‐type megakaryocyte dysplasia
por: Barosi, Giovanni, et al.
Publicado: (2023) -
Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2012) -
Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015) -
Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes
por: Villani, Laura, et al.
Publicado: (2021)